This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Bar-Ilan University, Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines S.e.c., Universitéde Montreal. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2026
Title: Maram Habashi: Innovator in Synthetic Cyclic Peptide Mimetics
Introduction
Maram Habashi is a notable inventor based in Ramat Gan, Israel. He has made significant contributions to the field of synthetic cyclic peptide mimetics, which have potential applications in diagnosing and treating amyloidogenic diseases. His innovative work has garnered attention in both academic and industrial circles.
Latest Patents
Maram Habashi holds a patent for "Synthetic cyclic peptide mimetics." This patent describes synthetic cyclic peptide mimetics that comprise alternating D-amino acids and L-amino acids, along with amino acid derivatives such as aza-amino acids and azasulfuryl-amino acids. The cyclic peptide mimetics may also be conjugated to another agent via a linker to form cyclic peptide mimetic conjugates. These mimetics are designed for use as diagnostic or therapeutic agents in the context of amyloidogenic diseases. He has 1 patent to his name.
Career Highlights
Throughout his career, Maram has worked with prestigious institutions, including Bar-Ilan University and Université de Montreal. His research has focused on the development of innovative peptide mimetics that can address critical health challenges.
Collaborations
Maram has collaborated with notable colleagues such as Shai Rahimipour and Michal Richman. Their combined expertise has contributed to advancements in the field of peptide research.
Conclusion
Maram Habashi's work in synthetic cyclic peptide mimetics represents a significant advancement in the field of biomedical research. His innovative approaches have the potential to lead to new diagnostic and therapeutic solutions for amyloidogenic diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile